Cargando…
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that exceeds 35 years in young patients, but its natural history might be interrupted by thrombotic, fibrotic, or leukemic events, with respective 20-year rates of 26%, 16%, and 4%. Current treatment strategies in...
Autores principales: | Tefferi, Ayalew, Vannucchi, Alessandro M., Barbui, Tiziano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632660/ https://www.ncbi.nlm.nih.gov/pubmed/34480106 http://dx.doi.org/10.1038/s41375-021-01401-3 |
Ejemplares similares
-
Polycythemia vera treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018) -
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
por: Barbui, T, et al.
Publicado: (2015) -
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera
por: Carobbio, Alessandra, et al.
Publicado: (2022) -
An agenda for future research projects in polycythemia vera and essential thrombocythemia
por: Barbui, Tiziano, et al.
Publicado: (2020) -
Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera
por: Barbui, Tiziano, et al.
Publicado: (2018)